These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
186 related articles for article (PubMed ID: 39170616)
1. Better clinical outcomes and lower triggering of inflammatory cytokines for allogeneic hematopoietic cell transplant recipients treated in home care versus hospital isolation - the Karolinska experience. Ringdén O; Svahn BM; Moll G; Sadeghi B Front Immunol; 2024; 15():1384137. PubMed ID: 39170616 [TBL] [Abstract][Full Text] [Related]
2. Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care. Ringdén O; Remberger M; Törlén J; Finnbogadottir S; Svahn BM; Sadeghi B Int J Hematol; 2021 May; 113(5):712-722. PubMed ID: 33544322 [TBL] [Abstract][Full Text] [Related]
3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Petersen SL Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527 [TBL] [Abstract][Full Text] [Related]
4. Home care during neutropenia after allogeneic hematopoietic stem cell transplantation in children and adolescents is safe and may be more advantageous than isolation in hospital. Ringdén O; Remberger M; Törlén J; Engström M; Fjaertoft G; Mattsson J; Svahn BM Pediatr Transplant; 2014 Jun; 18(4):398-404. PubMed ID: 24802347 [TBL] [Abstract][Full Text] [Related]
6. Home care during the pancytopenic phase after allogeneic hematopoietic stem cell transplantation is advantageous compared with hospital care. Svahn BM; Remberger M; Myrbäck KE; Holmberg K; Eriksson B; Hentschke P; Aschan J; Barkholt L; Ringdén O Blood; 2002 Dec; 100(13):4317-24. PubMed ID: 12393737 [TBL] [Abstract][Full Text] [Related]
7. Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. Hamadani M; Zhang MJ; Tang XY; Fei M; Brunstein C; Chhabra S; D'Souza A; Milano F; Phelan R; Saber W; Shaw BE; Weisdorf D; Devine SM; Horowitz MM Biol Blood Marrow Transplant; 2020 Jul; 26(7):1312-1317. PubMed ID: 32283185 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. Guru Murthy GS; Hari PN; Szabo A; Pasquini M; Narra R; Khan M; Abedin S; Chhabra S; Dhakal B; D'Souza A; Drobyski WR; Rizzo JD; Runaas L; Shah NN; Shaw B; Saber W; Fenske T; Hamadani M Biol Blood Marrow Transplant; 2019 Apr; 25(4):827-833. PubMed ID: 30572109 [TBL] [Abstract][Full Text] [Related]
9. Case-control comparison of at-home and hospital care for allogeneic hematopoietic stem-cell transplantation: the role of oral nutrition. Svahn BM; Remberger M; Heijbel M; Martell E; Wikström M; Eriksson B; Milovsavljevic R; Mattsson J; Ringdén O Transplantation; 2008 Apr; 85(7):1000-7. PubMed ID: 18408581 [TBL] [Abstract][Full Text] [Related]
10. Superior GVHD-free, relapse-free survival for G-BM to G-PBSC grafts is associated with higher MDSCs content in allografting for patients with acute leukemia. Fan Q; Liu H; Liang X; Yang T; Fan Z; Huang F; Ling Y; Liao X; Xuan L; Xu N; Xu X; Ye J; Liu Q J Hematol Oncol; 2017 Jul; 10(1):135. PubMed ID: 28676100 [TBL] [Abstract][Full Text] [Related]
11. Many days at home during neutropenia after allogeneic hematopoietic stem cell transplantation correlates with low incidence of acute graft-versus-host disease. Ringdén O; Remberger M; Holmberg K; Edeskog C; Wikström M; Eriksson B; Finnbogadottir S; Fransson K; Milovsavljevic R; Omazic B; Svenberg P; Mattsson J; Svahn BM Biol Blood Marrow Transplant; 2013 Feb; 19(2):314-20. PubMed ID: 23089563 [TBL] [Abstract][Full Text] [Related]
12. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant. Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918 [TBL] [Abstract][Full Text] [Related]
13. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation. Desai A; Samara Y; Yang D; Ball B; Braun A; Koller P; Blackmon A; Agrawal V; Pourhassan H; Amanam I; Arslan S; Otoukesh S; Sandhu K; Aldoss I; Ali H; Salhotra A; Al Malki MM; Artz A; Becker P; Smith E; Stein A; Marcucci G; Forman SJ; Curtin P; Nakamura R; Pullarkat V Leuk Res; 2024 Oct; 145():107565. PubMed ID: 39208597 [TBL] [Abstract][Full Text] [Related]
14. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation. Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407 [TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients treated at home during the pancytopenic phase after allogeneic haematopoietic stem cell transplantation. Svahn BM; Ringdén O; Remberger M Bone Marrow Transplant; 2005 Sep; 36(6):511-6. PubMed ID: 16025151 [TBL] [Abstract][Full Text] [Related]
16. Outcomes with low dose anti-thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation. Chalchal H; Dhir V; Masurekar A; Atkins H; Bredeson C; Kennah M; Kekre N; Allan D; Vasudevan Nampoothiri R Eur J Haematol; 2024 Oct; 113(4):543-549. PubMed ID: 38979885 [TBL] [Abstract][Full Text] [Related]
17. Allogeneic hematopoietic cell transplantation using fludarabine plus myeloablative busulfan and melphalan confers promising survival in high-risk hematopoietic neoplasms: a single-center retrospective analysis. Edahiro T; Kawase T; Nagoshi H; Fujino K; Toishigawa K; Miyama T; Mino T; Yoshida T; Morioka T; Hirata Y; Noma M; Fujii T; Nishizawa M; Fukushima N; Ichinohe T Hematology; 2021 Dec; 26(1):186-198. PubMed ID: 33594942 [TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide. Greco R; Lorentino F; Nitti R; Lupo Stanghellini MT; Giglio F; Clerici D; Xue E; Lazzari L; Piemontese S; Mastaglio S; Assanelli A; Marktel S; Corti C; Bernardi M; Ciceri F; Peccatori J Front Immunol; 2019; 10():2319. PubMed ID: 31632401 [No Abstract] [Full Text] [Related]